ASCO 2022: TheraP: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (McRpc) Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603)

Cabazitaxel vs. Lu-PSMA – no difference in OS but better patient reported outcomes. Will probably be preferred treatment post taxane and AR-targeted agents.

Read the full article here

Related Articles